| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/28/2009 | US20090137782 Recognize aberrant glycosylated form of the EGFR; evident upon aberrant post-translational modification; cancer |
| 05/28/2009 | US20090137663 Therapeutic micro nutrient composition for drug delivery |
| 05/28/2009 | US20090137662 Synergy of dopamine d2 and adenosine a2 receptors activates pka signaling via beta/gamma dimers |
| 05/28/2009 | US20090137619 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| 05/28/2009 | US20090137596 G-protein inhibitor |
| 05/28/2009 | US20090137574 Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders |
| 05/28/2009 | US20090137536 Method for treating and preventing hyperparathyroidism |
| 05/28/2009 | US20090137494 Tumor-activated prodrug compounds and treatment |
| 05/28/2009 | US20090137453 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof |
| 05/28/2009 | US20090137036 Tweak receptor |
| 05/28/2009 | US20090137035 Tweak receptor |
| 05/28/2009 | US20090136980 screening for a therapeutic oligopeptide for treatment of tumor disorders; contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle |
| 05/28/2009 | US20090136970 Nogo receptor homologues and their use |
| 05/28/2009 | US20090136565 Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R |
| 05/28/2009 | US20090136539 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 05/28/2009 | US20090136535 useful for enhancing immune response to antigens; lack ganglioside binding activity; applicable to mucosal immunization in humans |
| 05/28/2009 | US20090136508 Method of diagnosing colon and gastric cancers |
| 05/28/2009 | US20090136507 HBM variants that modulate bone mass and lipid levels |
| 05/28/2009 | US20090136474 Stabilized Protease Composition |
| 05/28/2009 | US20090136463 Schwann Cell Bridge Implants and Phosphodiesterase Inhibitors to Stimulate CNS Nerve Regeneration |
| 05/28/2009 | US20090136455 Canine probiotic bifidobacteria pseudolongum |
| 05/28/2009 | US20090136429 Combination of Anticholinergics and Inhibitors of Phosphodiesterase Type 4 For The Treatment of Respiratory Disease |
| 05/28/2009 | US20090136421 PAI-2 conjugates for the treatment and imaging of cancer |
| 05/28/2009 | US20090136420 Neoplasm-specific polypeptides and their uses |
| 05/28/2009 | US20090136419 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders |
| 05/28/2009 | CA2705936A1 Use of omega-3-fatty acids for pain relief |
| 05/28/2009 | CA2705836A1 Treatment of oral pharyngeal dysphagia |
| 05/27/2009 | EP2062887A1 Novel aminopyridine derivative having aurora a-selective inhibitory activity |
| 05/27/2009 | EP2062597A1 Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same |
| 05/27/2009 | EP2062583A2 Therapeutic applications of pro-apoptotic benzodiazepines |
| 05/27/2009 | EP2062582A1 The antibiotics composition comprising beta-lactam antibiotics and buffers |
| 05/27/2009 | EP2062580A1 Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors |
| 05/27/2009 | EP2061782A1 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 05/27/2009 | EP2061561A1 Methods and compositions for treating cancer |
| 05/27/2009 | EP2061513A1 Method of treating hepatitis c patients |
| 05/27/2009 | EP2061505A2 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| 05/27/2009 | EP2061462A2 Treating pain, diabetes and lipid metabolism disorders |
| 05/27/2009 | EP2061453A2 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias |
| 05/27/2009 | EP2061452A2 Anti cancer use of caffeic acid and derivatives |
| 05/27/2009 | EP2061451A2 Bis(thiohydrazide amides) for treating melanoma |
| 05/27/2009 | EP2061444A2 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| 05/27/2009 | EP2061314A2 Compounds for improving learning and memory |
| 05/27/2009 | EP1878431A4 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues |
| 05/27/2009 | EP1877095B1 The use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy |
| 05/27/2009 | EP1807419B1 (2-carboxamido)(3-amino) thiophene compounds |
| 05/27/2009 | EP1789107B1 Medical stent provided with inhibitors of atp synthesis |
| 05/27/2009 | EP1299086A4 Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| 05/27/2009 | EP1292678B1 G-protein coupled receptors |
| 05/27/2009 | EP1250140B1 Combination ofan abl-, pdgf-receptor- and/or kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein |
| 05/27/2009 | EP1244448B1 Novel methods for the treatment and prevention of ileus |
| 05/27/2009 | EP1095275B1 Endogenous constitutively activated g protein-coupled orphan receptors |
| 05/27/2009 | EP1037651B1 Small peptides and methods for treatment of asthma and inflammation |
| 05/27/2009 | EP0871487B1 Dendritic cell stimulatory factor |
| 05/27/2009 | CN101443079A Antibacterial extracellular polysaccharide solvating system |
| 05/27/2009 | CN101443017A Medication against breast cancer and related diseases |
| 05/27/2009 | CN101443016A Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
| 05/27/2009 | CN101439182A Somatostatin receptor mediated tumor-targeted medicament composition |
| 05/27/2009 | CN101439039A Fortifier |
| 05/27/2009 | CN101439038A Medicinal preparation composed of non-steroidal anti-inflammatory medicine and misoprostol |
| 05/27/2009 | CN101439024A Abuse-resistant opioid dosage form |
| 05/27/2009 | CN101439016A Bendamustine and potentiating agent thereof carried by anti-cancer medicine sustained-release injection |
| 05/27/2009 | CN100491392C Blanched polyamine steroid derivatives |
| 05/27/2009 | CN100490900C Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition |
| 05/27/2009 | CN100490897C Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle |
| 05/27/2009 | CN100490894C Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals |
| 05/27/2009 | CN100490845C Herbal composition and its use in chemotheraphy |
| 05/27/2009 | CN100490820C Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
| 05/27/2009 | CN100490818C Methods for treating hepatitis delta virus infection with beta-L-2' deoxy-uncleosides |
| 05/27/2009 | CN100490817C Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| 05/27/2009 | CN100490805C Composition for the transdermal delivery of fentanyl |
| 05/26/2009 | US7538257 Fluid wound dressing comprising partially cured polyurethane |
| 05/26/2009 | US7538216 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 05/26/2009 | US7538125 Pioglitazone insulin sensitivity enhancer with the antidiabetic glimepiride; difference in mechanism of action avoids adverse reactions over long term use; oral dosage tablet; lactose excipient, hydroxypropylcellulose binder, magnesium stearate lubricant, calcium carbonate disintegrator; diabetes |
| 05/26/2009 | US7538122 Modulators of CCR5(chemokine) receptors; lymphadenopathy associated and human T-cell leukemia/lymphoma viruses; AIDS infections; autoimmune diseases; antiinflammatory agents; derivatives of 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one |
| 05/26/2009 | US7538099 Antiprogestin method and kit for reducing side effects associated with low dosage HRT, oral contraception and regulating menses |
| 05/26/2009 | US7538091 D-retro-inverso amino acid sequence transporter peptide conjugated to nucleic acid biological effector; translocation across the membrane of pancreatic B-cells |
| 05/26/2009 | US7537908 Using concentration of high mobility group 1 (HMG1) protein as evaluative tool in detection of infection and acute respiratory distress syndrome; treating obesity with high mobility group antagonist |
| 05/26/2009 | US7537899 Defects in periaxin associated with myelinopathies |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | US7537795 Agent is dissolved in water to form aqueous coating solution for coating extremely tiny skin piercing elements, solution is applied to skin piercing elements, dried, device is applied to skin of a living animal causing microprotrusions to pierce stratum corneum and deliver drug |
| 05/26/2009 | US7537785 Composition for treating vascular diseases characterized by nitric oxide insufficiency |
| 05/26/2009 | US7537773 Chemodenervating pharmaceutical as anti-inflammatory agent |
| 05/26/2009 | US7537759 Modulating angiogenesis |
| 05/26/2009 | US7537756 Using nestin-positive pancreatic stem cell to generate insulin producing beta cells; tissue engineering and repair; regenerative medicine |
| 05/26/2009 | US7537752 Mixture of chelate compound and active material in vehicle |
| 05/26/2009 | CA2445478C Retinol derivatives potentiation of active substances by micellar preparation |
| 05/26/2009 | CA2441441C Combination of a taxane and a cyclin-dependent kinase inhibitor |
| 05/26/2009 | CA2436537C Pharmaceutical compositions comprising tiotropium salts and antihistamines |
| 05/26/2009 | CA2411754C 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents |
| 05/26/2009 | CA2367017C Inhibitors of impdh enzyme |
| 05/26/2009 | CA2355077C Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 05/26/2009 | CA2342211C Antibiotic compositions for treatment of the eye, ear and nose |
| 05/26/2009 | CA2298523C Therapeutic process for inhibiting nf-.kappa.b |
| 05/26/2009 | CA2242879C Method for treating sexual dysfunctions |
| 05/22/2009 | WO2009064493A1 Tricyclic compounds as melanogenesis modifiers and uses thereof |
| 05/22/2009 | WO2009064492A1 Quinoline compounds as melanogenesis modifiers and uses thereof |
| 05/22/2009 | WO2009064298A1 Methods for treating obesity and obesity related diseases and disorders |
| 05/22/2009 | WO2009063995A1 Diagnosis and treatment of arteriosclerosis |
| 05/22/2009 | WO2009063992A1 Condensed pyridine derivative and use thereof |
| 05/22/2009 | WO2009063821A1 Heteroaryloxy quinazoline derivative |